Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

manilatimes.net · 2026-10-12

Dosed first patient in registrational Phase 3 DAYBreak CLL-306 trial comparing bexobrutideg with pirtobrutinib in relapsed/refractory CLL/SLL

TickrTrends take: Nurix Therapeutics, a company in which Gilead Sciences holds a significant investment stake, reported third quarter 2026 results that investors monitoring GILD's portfolio should consider as part of the broader valuation picture. TickrTrends currently rates GILD as overvalued, making the financial performance and progress of its invested companies relevant to assessing whether that valuation premium is justified by underlying asset quality. The corporate updates from Nurix will influence how markets evaluate Gilead's investment in the company and its potential returns, which could impact perspectives on GILD's overall valuation in the Healthcare sector.

Read the full story at manilatimes.net →